Founder and director of the Spanish Drug Induced Liver Injury (DILI) Registry -the first network specialized in the study of Drug Induced Liver Injury- and of the Spanish Latin-American DILI Network and the recently set-up Prospective European DILI Registry awarded by the European Association for the Study of the Liver (EASL). Appointed by the EASL as Chairman of the Clinical Practice Guidelines Council responsible for writing a new CPG on Drug Induced Liver Injury 2016. Chair of CIOMS (Council for International Organizations of Medical Sciences) working group on DILI 2017. Chair COST ACTION CA17112. Principal investigator of CIBERehd group. He leads the PAIDI CTS-1032 group, IP of IBIMA Group on Translational Clinical Pharmacology, Expert of the World Health Organization, the European Medicines Agency (EMA) and the Spanish Medicines Agency in the Evaluation of liver safety of drugs. Member of the steering committee of the Group of Special Interest in Hepatotoxicity (AASLD). Member of the working team on the Cholestatic and Drug-induced Liver Disease section of the EASL- HEPAMAP project. He is member of the expert panel of the EFSA (European Food Safety Authority) since 2016. Member of the Reviewing board for the EASL International Liver Congress (2013-2016). Partner of the H2020 JTI IMI TRANSBIOLINE project, and the COST grant proposal Prospective European Drug-Induced Liver Injury Network.

Prof. Andrade is Associate editor of Liver International (Q1) and member of the editorial board of: Hepatology (2012-2016) (D1) and Frontiers in Pharmacology (Q1). He published over 250 articles in peer-review journals, and 43 book chapters. He has an h-index of 47 and 9509 total citations by 6161 documents. 23 publications were cited more than 100 times and 40 original articles received more than 50 citations. He presented more than 340 communications in International & National Scientific Meetings. In the past 5 years, he has directed 10 PhD thesis included 2 international thesis.